Influence of Environmental and Community Factors on Psoriasis: A Comprehensive Review of Pollution, Urban Design, and Socioeconomic Risk Factors

• by Parsa Mokhtar, Josep Riera Monroig, Allison Kranyak, Wilson Liao

• April 2, 2026

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

• by Lin Cai, Xiaohua Wang, Litao Zhang, Guoqiang Zhang, Liming Wu, Baoqi Yang, Zudong Meng, Jihai Shi, Guangming Han, Aihua Wei, Shanshan Li, Yi Zhao, Juan Su, Nianjin Wei, Siying Liu, Ran Liu, Wei Liu, Min Fang, Xiaoqing Zhang, Jianzhong Zhang

• March 22, 2026

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

• by Andrea Surnit

• May 5, 2026

• 4 min

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

• by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

• May 17, 2026